When the prognostic good-risk leukemia patients (adapted to the European LeukemiaNET Genetic Risk Classification[22]) were segregated from all other patients (summarized as “higher-risk cohort”, Tables 1 and 2), the good-risk cohort trended to lower ASPP2 expression levels when compared to healthy donors (medians 4.6 versus 8.8). The gene discussed is TP53BP2; the disease is leukemia.